124012-42-6

Basic information

• Product Name: Galocitabine
• Synonyms: Galocitabine;Ro 09-1390;Galocytabine;N-(3,4,5-Trimethoxybenzoyl)-5'-deoxy-5-fluorocytidine;5'-Deoxy-5-fluoro-N4-(3,4,5-trimethoxybenzoyl)cytidine;N-[1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydro-4-pyrimidinyl]-3,4,5-trimethoxybenzamide
• CAS NO: 124012-42-6
• Molecular Formula: C₁₉H₂₂FN₃O₈
• Molecular Weight: 439.394
• Mol File: 124012-42-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.52 g/cm³
• Refractive Index: 1.617
• PKA: 6.80±0.40(Predicted)
• CAS DataBase Reference: Galocitabine(CAS DataBase Reference)
• NIST Chemistry Reference: Galocitabine(124012-42-6)
• EPA Substance Registry System: Galocitabine(124012-42-6)

Safety Data

• Hazardous Substances Data: 124012-42-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C19H22FN3O8/c1-8-13(24)14(25)18(31-8)23-7-10(20)16(22-19(23)27)21-17(26)9-5-11(28-2)15(30-4)12(6-9)29-3/h5-8,13-14,18,24-25H,1-4H3,(H,21,22,26,27)/t8-,13-,14-,18-/m1/s1

Upstream product

• 161599-31-1 Acetic acid (2R,3R,4R,5R)-4-acetoxy-2-[5-fluoro-2-oxo-4-(3,4,5-trimethoxy-benzoylamino)-2H-pyrimidin-1-yl]-5-methyl-tetrahydro-furan-3-yl ester 
• 4521-61-3 3,4,5-Trimethoxybenzoyl chloride 
• 161599-46-8 (2R,3R,4R,5R)-2-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-5-methyl-tetrahydrofuran-3,4-diyl diacetate 
• 27821-07-4 1,2,3-tri-O-acetyl-5-deoxy-β-D-ribofuranose 
• 2022-85-7 Flucytosine 
• 1380532-03-5 N-(5-fluoro-2-((trimethylsilyl)oxy)pyrimidin-4-yl)-3,4,5-trimethoxybenzamide 

Downstream Products

• 3086-62-2 3,4,5-trimethoxybenzamide 
• 66335-38-4 5'-deoxy-5-fluorocytidine 
• 118-41-2 Eudesmic acid 
• 69260-71-5 doxifluridine 

Relevant articles and documents

Rapid continuous synthesis of 5′-deoxyribonucleosides in flow via Br?nsted acid catalyzed glycosylation

A general, green, and efficient Br?nsted acid-catalyzed glycosylation serves as a key step in the one-flow, multistep syntheses of several important 5′-deoxyribonucleoside pharmaceuticals.

Process for producing N4 -acyl-5'-deoxy-5-fluorocytidine compounds

A novel process for producing derivatives of the anti-tumor agent N4 -acyl-5'-deoxy-5-fluorocytidine using the novel 5'-deoxy-5-fluoro-N4, 2'-0,3'-0-triacylcytidine derivatives as intermediates is provided. 5-Deoxy-1,2,3-tri-0-acyl-β-D-ribofuranoside is reacted with 5-fluorocytosine to produce 5'-deoxy-2',3'-di-0-acyl-5-fluorocytidine, followed by acylation, to produce the novel intermediate 5'-deoxy-5-flouro-N4,2'-0,3'-0-triacylcytidine. The acyl radicals of this intermediate are selectively de-0-acylated to obtain N4 -acyl-5'-deoxy-5-fluorocytidine derivatives. From fluorocytosine, N4 -acyl-5'-deoxy-5-fluorocytidine derivatives can be obtained through few steps in high yield, an in satisfactory purity.